Nuvalent(NUVL) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results Updates from the ongoing Phase 1/2 ARROS-1 and ALKOVE-1 clinical trials expected at a medical meeting in the second half of 2024 Strong financial position with operating runway anticipated into 2027 Recent Pipeline Progress and Anticipated Milestones ROS1 Program ALK Program HER2 Program • Nuvalent presented new preclinical data at the American Association for Cancer Re ...